

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application: Hoon HAN *et al.*

U.S. Application No.: 10/579,070

Confirmation No. 3303

Filed: May 11, 2006

Title: METHOD OF ISOLATING AND
CULTURING MESENCHYMAL STEM
CELL DERIVED FROM UMBILICAL
CORD BLOOD

Art Unit: 1633

Examiner: Fereydoun G. SAJJADI

Atty. Docket No.: 36470-231114

Customer No.

26694

PATENT TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Madam:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. Copies of **Documents C1-C9** are enclosed.

Applicants wish to draw the Examiner's attention to a related application (Appl. No. 10/579,091, Publ. No. 2007/0105221) that may be relevant to prosecution. Applicants are submitting two Office Actions of the aforementioned application, which are Documents C1 and C2.

This Information Disclosure Statement is filed in conjunction with a Request for Continued Examination. Accordingly, no additional fees are required. Applicants hereby petition that the Information Disclosure Statement be considered.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicants have not submitted copies of U.S. patents and U.S. patent applications. Applicants submit herewith copies of non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

We believe that no additional fees are required with the submission of this IDS. However, the Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0261, under Order No. 36470-231114.

Respectfully submitted,

Dated: January 30, 2009

/Keith G. Haddaway/

Keith G. Haddaway, Ph.D.
Registration No. 46,180
VENABLE LLP
P.O. Box 34385
Washington, DC 20043-9998
202-344-8009
202-344-8300 (fax)

DC2/1011799